Cosette Patent-Cliff Exposure & CMS Drug Spending Portfolio
Cosette (US): 14 reconciled FDA prescription therapies (3.0% 2025 to 2030 cliff risk), $66.7M 2024 CMS Part D & Medicaid spend, and 47 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | US |
| Reconciled FDA Portfolio Therapies | 14 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 3.0% |
| Primary Portfolio LOE Date | 2026-01-01 |
| 2024 CMS Total Public Spend | $66.7M |
| 2024 Medicare Part D Spend | $52.2M |
| 2024 Medicaid Spend | $14.6M |
| California HCAI SB 17 Filings | 47 WAC filings (max 32.9% 2-yr change) |